491577-82-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-Thiazolecarboxylic acid, 4-(4-aminophenyl)-, ethyl ester is used as a pharmaceutical agent for the treatment of various diseases. Its unique structure and potential biological and pharmacological properties make it a promising candidate for drug discovery and development.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-Thiazolecarboxylic acid, 4-(4-aminophenyl)-, ethyl ester is utilized for the synthesis of new compounds with potential therapeutic applications. Its versatile chemical structure allows for the exploration of various chemical modifications to enhance its pharmacological properties and improve its efficacy as a drug candidate.
Although the compound has not been extensively studied, its structure suggests that it may have potential applications in various industries, such as:
Used in Pharmaceutical Industry:
2-Thiazolecarboxylic acid, 4-(4-aminophenyl)-, ethyl ester is used as a drug candidate for the development of new therapeutic agents targeting a range of diseases. Its unique chemical structure and potential pharmacological properties make it a valuable asset in the search for novel treatments.
Used in Chemical Research Industry:
In the chemical research industry, 2-Thiazolecarboxylic acid, 4-(4-aminophenyl)-, ethyl ester is employed as a starting material for the synthesis of new compounds with potential applications in various fields, including materials science, agrochemistry, and environmental chemistry. Its versatile structure allows for the exploration of new chemical reactions and the development of innovative products.

Upstream product

• 53101-04-5 ethyl 4-(4-nitrophenyl)-1,3-thiazole-2-carboxylate 
• 16982-21-1 ethyl 2-amino-2-thioxoacetate 
• 23442-14-0 4-aminophenacyl bromide 
• 99-81-0 4-Nitrophenacyl bromide 

Downstream Products

• 950603-75-5 C₃₄H₄₈ClN₃O₅SSi 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of N,N-disubstituted-4-arylthiazole-2-methylamine derivatives as cholesteryl ester transfer inhibitors

Cholesteryl ester transfer protein (CETP) has been identified as a potential target for cardiovascular disease (CVD) for its important role in the reverse cholesteryl transfer (RCT) process. In our previous work, compound 5 was discovered as a moderate CETP inhibitor. The replacement of the amide linker by heterocyclic aromatics and then a series of N,N-substituted-4-arylthiazole-2-methylamine derivatives were designed by utilizing a conformational restriction strategy. Thirty-six compounds were synthesized and evaluated for their CETP inhibitory activities. Structure-activity relationship studies indicate that electron donor groups substituted ring A, and electron-withdrawing groups at the 4-position of ring B were critical for potency. Among these compounds, compound 30 exhibited excellent CETP inhibitory activity (IC50 = 0.79 ± 0.02 μM) in vitro and showed an acceptable metabolic stability.

HEDGEHOG INHIBITORS

Described herein are compounds, pharmaceutical compositions and methods for the inhibition of Hedgehog signaling. Said compounds, pharmaceutical compositions and methods have utility in the treatment of human and veterinary disease and disorders.

NOVEL CC-1065 ANALOGS AND THEIR CONJUGATES

This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.

GUT MICROSOMAL TRIGLYCERIDE TRANSPORT PROTEIN INHIBITORS

Compounds represented by formula (I): are inhibitors of gut microsomal triglyceride transfer protein. Such compounds are useful in treating diseases or conditions such as diabetes and obesity, along with patients are risk for developing such diseases or conditions.

Synthesis and evaluation of potent and selective β3 adrenergic receptor agonists containing heterobiaryl carboxylic acids

The design, synthesis, and SAR of a novel series of heterobiaryl phenethanolamine β3 adrenergic receptor agonists are described. The furan analogue 49 was shown to elicit a significant dose-dependent lowering of plasma glucose in a rodent model

VIRAL POLYMERASE INHIBITORS

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula (I): wherein wherein A, B, R2, R3, L, M1, M2, M3, M4, Y1, Y0, Z and Sp are as defined in claim 1, or a salt thereof, as an inhibitor of HCV NS5B polymerase.

Viral polymerase inhibitors

An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein R1 is selected from: H, haloalkyl, (C1-6)alkyl, (C2-6)alkenyl, (C3-7)cycloalkyl, (C2-6)alkynyl, (C5-7)cycloalkenyl, 6 or 10-membered aryl, Het all optionally substituted; R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C6-10)bicycloalkyl, 6- or 10-membered aryl, or Het all optionally substituted; B is N or CR5, wherein R5 is H, halogen, haloalkyl, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; X is N or CR5; D is N or CR5; each of Y1 and Y2 is independently O or S; Z is O, N, or NRz wherein Rz is H, (C1-6)alkyl, (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; R3 and R4 are each independently H, (C1-6)alkyl, first (C3-7)cycloalkyl or 6- or 10-membered aryl, Het (C1-6)alkyl-6- or 10-membered aryl, (C1-6)alkyl-Het; or each R3 and R4 are independently covalently bonded together to form second (C3-7)cycloalkyl, or heterocycle, all optionally substituted; or when Z is N, either R3 or R4 are independently covalently bonded thereto to form a nitrogen-containing heterocycle; R7 is H, (C1-6 alkyl), (C3-7)cycloalkyl or (C1-6)alkyl-(C3-7)cycloalkyl; or R7 is covalently bonded to either of R3 or R4 to form a heterocycle; A is (C1-6) alkyl-CONHR8 wherein R8 is-6- or 10-membered aryl, or Het; or A is a 6- or 10-membered aryl, or Het said aryl or Het being optionally substituted; or a salt or a derivative thereof; such compounds being potent inhibitors of HCV NS5B polymerase.